Nkure Therapeutics
Bengaluru cell therapy company founded in 2022 by former NIH regenerative medicine director Dr Mahendra Rao, developing off-the-shelf allogeneic natural killer (NK) cell therapies to make cancer immunotherapy affordable in India; it holds exclusive licences to CAR technologies and partners with CRISPR Therapeutics on CTX112.
Headquarters
Bengaluru, India
Year Founded
2022
Founders
Mahendra Rao (founder)
Country
India
Financial Information
Funding Stage
Pre-Series A
Recent Funding
Not disclosed
Funding By
Endiya Partners, Kotak Investment Advisors, Featherlite, angel investors
Core Technology
Allogeneic NK cell platform with licensed CAR technology (CAR-NK)
Product Type
Cell Therapy
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: No
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Exclusive licences to CAR and related cell-therapy technologies
Partnerships
Pharma Collaborations
CRISPR Therapeutics (CTX112 partnership for India)
Academic / Hospital Tie-ups
C-CAMP Bengaluru; Department of Biotechnology grant funding
CRO/CDMO Partnerships
CDMO agreements in India and the United States
Market & Differentiation
Off-the-shelf NK cells targeting a fraction of autologous CAR-T cost and complexity